Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Shanxi C&Y Pharmaceutical Group Co Ltd (300254)

Shenzhen
Currency in CNY
Disclaimer
8.72
+0.21(+2.47%)
Closed
300254 Scorecard
Fair Value
Unlock Value
Day's Range
8.308.98
52 wk Range
4.9811.60
Bid/Ask
8.72 / 8.73
Prev. Close
8.51
Open
9.6
Day's Range
8.3-8.98
52 wk Range
4.98-11.6
Volume
13,410,220
Average Volume (3m)
13,635,860
1-Year Change
41.79%
Shares Outstanding
241,618,563
Fair Value
Unlock
Dividends Payment Streak
Unlock
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about 300254?
Vote to see community's results!
or

Shanxi C&Y Pharmaceutical Group Co Ltd Company Profile

ShanXi C&Y Pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of medicine and health food products. It offers anti-infective drugs, anti-allergic drugs, respiratory system drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, antidepressants, medicines, pharmaceutical raw materials, and intermediates, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, Mezlocillin sodium sulbactam sodium for injection, Ebastine tablets, Tamsulosin hydrochloride sustained release capsules, Cinacalcet hydrochloride tablets, Apixaban tablets, Rivaroxaban tablets, Flouxetine hydrochloride capsules, Ambroxol hydrochloride dispersible tablets, Smectite powder, Vitamin AD drops, and Baoling Yunbao oral liquid, as well as provides DNA gene preservation services. It also provides medical and health services and commercial services, such as medical diagnosis, gene preservation, and pregnancy environment testing services. The company was formerly known as Shanxi C&Y Pharmaceutical Co., Ltd. and changed its name to Shanxi C&Y Pharmaceutical Group Co., Ltd. in September 2014. Shanxi C&Y Pharmaceutical Group Co., LTD. was founded in 2005 and is headquartered in Datong, China.

Employees
0
Market
China
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.